BioSpace News Archive

Theranexus and the Beyond Batten Disease Foundation, have announced the initial results of their Phase I/II clinical trial for juvenile Batten disease.

Fresenius Medical Care North America, the nation’s leading renal care provider, has won a major grant from the Mississippi Department of Health’s Office of Rural Health and Primary Care to expand kidney education through virtual reality.

joimax®, the German-based market leader in technologies and training methods for full-endoscopic and minimally invasive spinal surgery, has appointed Mr. Maximilian Ries and Mr. Anthony Troncale to new executive positions, effective January 1.

To help life and health insurers accelerate their strategic modernization and digital transformation initiatives, Montoux Inc. (Montoux), a leading actuarial automation technology provider, today announced a strategic collaboration agreement (SCA) with Amazon Web Services, Inc. (AWS).

NovAccess Global Inc. announced the availability of its latest monthly installment in a series of fireside chat interviews, with additional sessions to be made available as company developments arise.

Cardiac Insight, Inc. announced that researchers at Stanford Medicine selected the company’s Cardea SOLO™ wearable ECG system for a medical study entitled: Serial 7-Day Electrocardiogram Patch Screening for Atrial Fibrillation in High-Risk Older Women by the CHARGE-AF Score The study set out to measure asymptomatic atrial fibrillation in older women since AF is associated with an increased risk of stroke.

Crown Bioscience announced their newly published study in PLOS ONE, a journal of the Public Library of Science, demonstrating the establishment and application of a highly clinically relevant 3D in vitro PDX-derived organoid biobank for higher-throughput screening for cancer drug discovery.

Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company, today announced positive topline results from its Phase 2b clinical study of AR882 for the treatment of chronic gout, providing a strong foundation to advance into Phase 3 clinical development.

Integral Molecular, the industry leader in antibody discovery for membrane proteins, has published the targeting mechanism enabling best-in-class specificity of its Claudin 6 antibody CTIM-76 being developed for cancer therapy with Context Therapeutics.

A trial led by City of Hope, one of the largest cancer research and treatment organizations in the nation, contributed to the U.S. Food and Drug Administration’s approval of mosunetuzumab, the first bispecific antibody to treat people with relapsed or difficult to treat follicular lymphoma, a type of non-Hodgkin lymphoma, after they have received two or more standard therapies.